Lilly’s obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some
Eli Lilly has surpassed analysts’ highest hopes for the efficacy of retatrutide, linking the triple agonist to 28.7% weight loss and a 75.8% reduction in pain scores in patients with…
